This page shows the latest Inclisiran news and features for those working in and with pharma, biotech and healthcare.
Low-density lipoprotein cholesterol level reduction was sustained over four years. Novartis has announced new long-term Leqvio (inclisiran) data, showing sustained efficacy and safety over a four-year period in
Also, Novartis’ Leqvio (inclisiran) – which has the added convenience of only being injected once every six months – has been approved in Europe but has only just started to be rolled out.
Inclisiran represents a potential game-changer in preventing thousands of people from dying prematurely from heart attacks and strokes,” said NICE deputy chief executive, Meindert Boysen. ... Inclisiran is particularly attractive because it only needs
mark. The company also said it had resubmitted its cholesterol-lowering med inclisiran in the US, after the Food and Drug Administration (FDA) issued a Complete Response Letter earlier this year ... In the EU, inclisiran is already approved under the
Leqvio (inclisiran) is a small interfering RNA (sIRNA) with a new mechanism of action that allows it to deliver effective and sustained low-density lipoprotein cholesterol (LDL-C) reduction for patients
Leqvio ( inclisiran) is a potential first-in-class treatment for high cholesterol in Europe for patients with hypercholesterolemia or mixed dyslipidemia.
More from news
Approximately 10 fully matching, plus 7 partially matching documents found.
Perhaps the most widely known of these was the deal struck with Novartis for access to its novel cholesterol drug, Leqvio (inclisiran).
8. Inclisiran from The Medicines Company (now a Novartis wholly owned subsidiary) is being reviewed for approval in hypercholesterolemia in the US and the EU. ... Inclisiran must leverage its strong efficacy and twice-a-year dosing to succeed.
Meanwhile, there’s considerable excitement about Novartis-partnered cholesterol-lowering therapy inclisiran, which is also up for an FDA decision this year and has been tipped to become a mega-blockbuster
Alnylam has three more RNAi medicines in its late stage pipeline: Fitusiran in haemophilia, being co-developed with Sanofi; inclisiran for hypercholesterolemia being co-developed by the Medicines Company; and lumisiran
More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.
We are a fully integrated agency that is 100% dedicated to creating standout communications in healthcare. Our success starts by...